What's Happening?
A federal jury in Massachusetts has ruled in favor of Abiomed Inc., a subsidiary of Johnson & Johnson, in a patent trial against Maquet Cardiovascular LLC, a unit of Getinge. The jury found that the patent claim asserted by Maquet over heart-pump technology
was invalid due to a lack of written description and enablement. Additionally, the jury concluded that Abiomed's Impella devices did not infringe on the patent under the reverse doctrine of equivalents. The verdict is a significant win for Abiomed, as it allows the company to continue the production and sale of its Impella heart pumps without the threat of infringement claims.
Why It's Important?
This legal victory is crucial for Abiomed and Johnson & Johnson as it secures their position in the competitive heart-pump market. The Impella devices are a key product line for Abiomed, and the ruling allows the company to maintain its market share without the risk of costly litigation or potential damages. The decision also highlights the importance of robust patent documentation and the challenges companies face in protecting their intellectual property. For the broader medical device industry, this case underscores the complexities of patent law and the need for clear and comprehensive patent filings.
